En kombinasjonsbehandling med et utvalg av valgmulighetene som her er listet opp, vil sammen med livsstilsendringer gi muligheter for å kunne reversere og kontrollere selv fremskridende diagnoser.
- Benzaldehyde i syklodextrin
- Tagamet (Cimetidine) (L)
- Dipyridamole (L)
- Miltefosine (L)
- Pau d`arco
- Vitamin D
- 3-bp og paracetamol
- Atenolol (L)
- Chaga (Betulinic acid)
- Chapparal, Larrea divaricata
- Dacarbazine IPT (L)
- Disulfiram og sink i form av iodide, acetate eller glukonate (L)
- Dithiodinicotinic acid
- DNCB (L)
- Garden of life RM-10 eller lignende
- Interferon (L)
- Intravenøs vitamin C med menadione + øvrige synergister
- IP6 + inositol
- Lovastatin (L)
- Mebendazole (L)
- Neupogen (G-CSF)
- Newcastle virus (L)
- Nivolumab og ipilimumab + denosumab
- Selen (N)
- TIL (tumor infiltrating lymphocytes)
- Timian (te og omslag)
- Vitamin C
- www.hadassah-med.com, Jerusalem
- DIPYRIDAMOLE FOR TREATMENT OF MELANOMA. The Lancet, Volume 325, Issue 8430, Page 693, 23 March 1985. These doctors for the past 11 years had been maintaining melanoma patients with Clark’s level IV and III disease on dipyridamole, 300 mg a day. Thirty of these patients were maintained on this dose of dipyridamole. Of them, 26 had level IV disease and four had level III disease. At five years, the survival of the level IV patients was 74%. The five-year survival for the total of the 30 of level IV and III disease was 77%. None of the level III patients died.
- Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex®) In conclusion, there is evidence that miltefosinecaused a specific topical regression of the cutaneousmetastases of the aggressive melanoma of ourpatient. This indicates that topical miltefosine treat-ment can be efficient in the treatment of recurrentmelanoma although no general conclusions can bedrawn from this single case, and other reports on thetopical effect of miltefosine on cutaneous melanomametastases are sparse.
- The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321-0.
- Analysis of growth-inhibitory mechanisms of flubendazole in malignant melanoma cells. PharmDr. Kristýna Čáňová. Hradec Králové, 2018
- Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy. Case Rep Oncol 2019;12:829–833
- Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report. Melanoma Research: June 2019 – Volume 29 – Issue 3 – p 322-324
- Long-term complete remission of cutaneous melanoma metastases in association with a folk remedy. J Am Acad Dermatol. 2005 Apr;52(4):713-5.
Kalorirestriktiv ketogen diett (høy fett, lav karb og moderat med protein).
- Benyttes sammen med en diett fri for geranylgeraniol
- Boswellia (3-4 g) og bromelain
- Curcumin (6-8 g)
- Cantron/Protocel 50
- Chaga (Betulinic acid)
- Chlorella (N)
- Chloroquine + Vemurafenib (BRAF hemmer)
- Autogafi hemmer->hemmer utvikling av resistens til BRAF hemmere
- CUSP9v3 Treatment Protocol
- Germanium 132
- GLA 1-4 g
- Melatonin (15-40 mg daglig)
- Minerval/2OHOA/2-hydroxyoleic acid
- Newcastle Virus
- Perillyl Alcohol (POH)
- Selenium 800-1000 ug (helst i form av selenite)
- Sodium Phenylbutyrate/Anti-neoplastons
- Vitamin D3 (5000 iu daglig)
- Vitamin E (Delta Tocotrienols)
- Vorasidenib eller ivosidenib (IDH hemmere)
- Cyclopamine + lovastatin
Hjernesvulst hos barn
- In Search of a Breakthrough Therapy for Glioblastoma Multiforme. Neuroglia 2018, 1(2), 292-307
- A Survival Guide to GBM (Glioblastoma)
- ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma. International Journal of Radiation Oncology Biology Physics
Available online 30 June 2020
- In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release. 2011 Jul 28. Our results showed that Tween® 80 coated Compritol® and Precirol® LN can effectively inhibit the growth of C6 glioma cells in vitro and suggest that edelfosine-loaded LN represent an attractive option for the enhancement of antitumor activity on brain tumors in vivo.
- A phase 1/2 study of orally administered synthetic hypericin (Johannesurt) for treatment of recurrent malignant gliomas.Cancer. 2011 Mar 31. doi: 10.1002/cncr.26123. [Epub ahead of print] Synthetic hypericin administered orally appeared to provide stabilization or a slight (<50%) decrease in tumor volume (coded as stable disease) at 3 months for 7 of 42 patients (17%) and produced a tumor reduction >50% (partial response) in 2 patients (5%). Seventeen patients (40%) survived for 3 months on daily synthetic hypericin at dose levels of 0.33 ± 0.070 mg/kg daily. The mean maximum tolerated dose was 0.40 ± 0.098 mg/kg daily. Twelve patients continued on hypericin therapy beyond 3 months. The median survival was 26 weeks (Kaplan-Meier method).
- Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther. 2009 Jun;8(2):195. There were remarkably inhibitory effects of artmeter on brain glioma growth and angiogenesis in SD rats and the mechanism that artemether inhibited brain glioma growth might be penetrating the blood-brain barrier and inhibiting angiogenesis.
- Lactate promotes glioma migration by TGF-β2–dependent regulation of matrix metalloproteinase-2.Neuro Oncol. 2009 August; 11(4): 368–380. Lactate dehydrogenase type A (LDH-A) is a key metabolic enzyme catalyzing pyruvate into lactate and is excessively expressed by tumor cells. Transforming growth factor-β2 (TGF-β2) is a key regulator of invasion in high-grade gliomas, partially by inducing a mesenchymal phenotype and by remodeling the extracellular matrix.
- Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma. Front. Nutr., 05 October 2018
- Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up. Front. Nutr., 29 March 2018
- Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond). 2010 Apr 22;7:33. This is the first report of confirmed GBM treated with standard therapy together with a restricted ketogenic diet. As rapid regression of GBM is rare in older patients following incomplete surgical resection and standard therapy alone, the response observed in this case could result in part from the action of the calorie restricted ketogenic diet. Further studies are needed to evaluate the efficacy of restricted ketogenic diets, administered alone or together with standard treatment, as a therapy for GBM and possibly other malignant brain tumors.
- Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. J Cancer Res Ther. 2009 Sep;5 Suppl 1:S7-15. We propose a different approach to brain cancer management that exploits the metabolic flexibility of normal cells at the expense of the genetically defective and less metabolically flexible tumor cells. This approach to brain cancer management is supported from recent studies in orthotopic mouse brain tumor models and in human pediatric astrocytoma treated with calorie restriction and the ketogenic diet. Issues of implementation and use protocols are discussed.
- The ERGO trial: A pilot study of a ketogenic diet in patients with recurrent glioblastoma.J Clin Oncol 28, 2010 (suppl; abstr e12532). Conclusions: This ketogenic diet is feasible and safe and has antitumor activity in glioma patients. The combination of the diet with antiangiogenic agents appears promising according to theoretical considerations and our preliminary data. Randomized trials evaluating the therapeutic potential of ketogenic diets in tumor patients are warranted.
- COMPLETE, DURABLE RESPONSE OF A RECURRENT UNRESECTABLE GRADE III GLIOMA TO A REPURPOSED DRUG REGIMEN. Neuro-Oncology 20(suppl_6):vi12-vi12 · November 2018
- Modulation of glioma risk and progression by dietary nutrients and anti-inflammatory agents. Nutr Cancer. 2011;63(2):174-84. Scientific evidence suggests that certain natural dietary components, such as phytoestrogens, flavonoids, polyunsaturated fatty acids, and vitamins, may exert a protective effect against gliomas by changing the nature of the interaction between genetics and environment. Similarly, certain antiinflammatory drugs and dietary modifications, such as methionine restriction and the adoption of low-calorie or ketogenic diets, may take advantage of glioma and normal glial cells’ differential requirements for glucose, methionine, and ketone bodies and may, therefore, be effective as part of preventive or treatment strategies for gliomas.
- Treatment of Glioblastoma with Intravenous Taurolidine. First Clinical Experience. ANTICANCER RESEARCH 24: 1143-1148 (2004)
- Minerval®: Treatment of glioma and other types of cancer
- Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Elife. 2017 Jan 17;6. pii: e19671.
- Does valganciclovir have a role in glioblastoma therapy? Neuro Oncol. 2014 Mar; 16(3): 330–331.
- Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma? Neurochem Res. 2019 Apr 25.
- Investigational New Drugs for Brain Cancer. Expert Opin Investig Drugs. 2016 Aug; 25(8): 937–956.
- A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience. J Neurosurg Sci. 2019 Jun;63(3):286-291.
- Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs. Front Mol Neurosci. 2018; 11: 159.
- Perioperative Study of Vorasidenib Shows Promise for Patients with Low-Grade Glioma. Cancernetwork
- Statins affect human glioblastoma and other cancers through TGF-β inhibition. Oncotarget. 2019 Mar 1;10(18):1716-1728.
- A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Mol Cancer Ther, 10 (1), 90-103 Jan 2011